Catalog No.
Product Name
Application
Product Information
Citations
-
Drug-Linker Conjugates for ADC
ST8155AA1 is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs) with a mechanism targeting histone deacetylases (HDACs). This compound exhibits significant antitumor activity, making it a valuable tool for cancer research, particularly in the development of targeted therapies. Its application in ADCs enhances the specificity and efficacy of therapeutic agents against tumor cells. -
Drug-Linker Conjugates for ADC
HS-(CH2)3CO-L-Ala-D-Ala-L-Ala-NH-CH2-S-(CH2)5-CO-DM is a peptide-cleavable drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. The maytansinoid moiety (DM) enhances cytotoxicity, making this conjugate an effective tool for targeted cancer therapy. Its unique chemical structure allows for precise release of the therapeutic agent in the tumor microenvironment, facilitating specific delivery and reduced systemic toxicity. This reagent is suitable for research focusing on ADC development and optimization. -
Drug-Linker Conjugates for ADC
Mal-VC-PAB-ABAEP-Azonafide is a drug-linker conjugate designed for use in antibody-drug conjugate (ADC) applications. It combines the potent cytotoxic effects of Azonafide with the Mal-VC-PAB linker to enhance targeted delivery and efficacy against tumor cells. This reagent is utilized in research focusing on advanced therapeutic strategies for cancer treatment, specifically in the development of ADCs that aim to improve therapeutic selectivity while minimizing systemic toxicity. -
Drug-Linker Conjugate For ADC
Val-Cit-PAB-MMAF is a drug-linker conjugate designed for antibody-drug conjugates (ADCs). This compound integrates a peptide linker, Val-Cit-PAB, with MMAF, a highly effective inhibitor of tubulin polymerization. Val-Cit-PAB-MMAF is utilized in research focusing on targeted cancer therapies, enhancing the specificity and efficacy of ADCs through selective delivery mechanisms. -
Drug-Linker Conjugates for ADC
Gly-Mal-Gly-Gly-Phe-Gly-amide-methylcyclopropane-Exatecan serves as a potent drug-linker conjugate for antibody-drug conjugate (ADC) synthesis. This compound facilitates the targeted delivery of cytotoxic agents to cancer cells, enhancing therapeutic efficacy while reducing off-target effects. It is particularly valuable in the development of innovative cancer treatments, enabling precise targeting and improved pharmacokinetic profiles. -
Drug-Linker Conjugate for ADC
TGA-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features a topoisomerase 1 inhibitor and a cleavable linker, facilitating controlled release of the active drug upon target interaction. It is suitable for the synthesis of ADCs aimed at enhancing the specificity and efficacy of therapeutic agents in cancer research and treatment. -
Drug-linker Conjugate For ADC
MC-Gly-Gly-Phe-Exatecan analog 38 is a linker compound designed for use in antibody-drug conjugates (ADCs). This synthetic analog facilitates the delivery of cytotoxic agents to targeted cancer cells, enhancing therapeutic efficacy while minimizing off-target effects. It serves as a valuable tool in cancer research for the development and synthesis of various ADCs. -
Drug-Linker Conjugates for ADC
GDP-Fuc-AM-VcPAB-MMAE is a conjugate of the cytotoxic agent Monomethyl auristatin E (MMAE) linked via a specific linker system. This precursor molecule plays a critical role in the development of antibody-drug conjugates (ADCs), facilitating targeted delivery of therapeutics in cancer research. Its utilization in experimental studies aids in the exploration of ADC efficacy and potential treatment pathways for neoplastic diseases. -
Drug-Linker Conjugate for ADC
Ledadotin is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It comprises Auristatin F-hydroxypropylamide, a microtubule inhibitor, linked to a specialized PEG-based linker. This compound is utilized in the synthesis of the ADC Emiltatug ledadotin, making it valuable for targeted cancer therapies and related research applications. -
Drug-Linker Conjugates for ADC
DM21-L-G is a drug-linker conjugate designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the selective delivery of cytotoxic agents to targeted cells, enhancing therapeutic efficacy while minimizing off-target effects. Its application is critical in the development of targeted cancer therapies, enabling researchers to explore new avenues in precision medicine. -
Drug-Linker Conjugates for ADC
Amidate-VC-PAB-MMAF is a cleavable drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound combines the Amidate-VC-PAB linker with MMAF, a potent inhibitor of tubulin polymerization, to enhance the targeted delivery of therapeutic agents. By utilizing this linker, researchers can minimize off-target cytotoxicity while improving the efficacy of ADCs in cancer treatments and other applications in drug development. -
Drug-Linker Conjugates for ADC
PNU-EDA-Gly5 is an oligo-glycine linker designed for antibody-drug conjugate (ADC) synthesis, consisting of the DNA topoisomerase I inhibitor PNU-159682 linked to EDA-Gly5. This compound facilitates targeted delivery of cytotoxic agents while maintaining the activity of the payload, making it useful for the development of ADCs aimed at cancer therapies. Researchers can utilize PNU-EDA-Gly5 to explore novel therapeutic strategies in oncology and enhance the efficacy of targeted treatment modalities. -
Drug-Linker Conjugate for ADC
APL-1092 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, featuring the potent payload Exatecan. The structure incorporates a stable linker to facilitate precise delivery of the cytotoxic agent to targeted cells. APL-1092 is intended for research into targeted cancer therapies, offering a promising tool for studying the efficacy and mechanism of ADCs in various tumor models. -
Drug-Linker Conjugates for ADC
MB-VC-MGBA is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, featuring a potent antitumor activity mechanism. This compound employs MGBA, a minor-groove-binding DNA-alkylating agent, connected through the linker MB-VC, providing effective targeted delivery in cancer therapy research. Its unique design facilitates precise targeting and enhances therapeutic efficacy for various malignancies. -
Drug-Linker Conjugates for ADC
Mc-Lys(PEG12)-Cap-Ala-Ala-PABC-exatecan is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features a unique ADC linker (Mc-Lys(PEG12)-Cap-Ala-Ala-PABC) combined with the potent DNA topoisomerase I inhibitor, Exatecan. It is particularly relevant for the development of targeted therapies against HER2-positive breast cancer, facilitating the selective delivery of cytotoxic agents to tumor cells while minimizing off-target effects. -
Drug-Linker Conjugates for ADC
XB010 drug-linker is a conjugate that combines MMAE with RED-601, specifically designed for the synthesis of antibody-drug conjugates (ADCs). This drug-linker facilitates targeted delivery of cytotoxic agents to cancer cells, enhancing therapeutic efficacy while minimizing off-target effects. Researchers utilize XB010 for the development of ADCs aimed at improving anticancer treatments and studying the mechanisms of drug action in tumor biology. -
Drug-Linker Conjugates for ADC
DBA-DM4 is a drug-linker conjugate designed for use in antibody-drug conjugate (ADC) applications. It combines the potent tubulin inhibitor DM1 with the SPDP linker to facilitate targeted delivery of cytotoxic agents to cancer cells. DBA-DM4 is utilized in research aimed at enhancing the efficacy and selectivity of therapeutic antibodies in oncology, making it a valuable tool for the development of novel cancer treatments. -
Drug-Linker Conjugate for ADC
Mal-PEG8-Phe-Lys-PAB-Exatecan is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features a degradable linker composed of Mal-PEG8-Phe-Lys-PAB, covalently linked to the potent cytotoxic agent Exatecan. It is utilized in research focusing on targeted cancer therapies, enabling the effective delivery of cytotoxic agents to cancer cells while minimizing off-target effects. -
Drug-Linker Conjugates for ADC
N-(Hexanoyloxy)succinimide-MMAE is a drug-linker conjugate designed for antibody-drug conjugates (ADCs). It features a hexanoyloxy group and a degradable PEG linker, which facilitates the delivery of the cytotoxic agent MMAE to target cells. This compound shows significant antitumor activity and is useful in the development of targeted cancer therapies, enhancing the efficacy of ADCs by minimizing off-target effects. -
Drug-Linker Conjugate For ADC
LP-6 TFA is a drug-linker conjugate designed for antibody-drug conjugate (ADC) synthesis. This compound integrates an Eg5 inhibitor with a linker, facilitating targeted drug delivery and enhancing therapeutic efficacy. It is suitable for research applications focused on the development and optimization of ADCs in cancer therapy. -
Drug-Linker Conjugate for ADC
MC-Val-Cit-PAB-MMAF is a drug-linker conjugate designed for Antibody-Drug Conjugates (ADCs). It employs the potent tubulin inhibitor MMAF, which is covalently linked via the cathepsin-cleavable peptide MC-Val-Cit-PAB. This compound exhibits significant antitumor activity, making it valuable for research applications in cancer therapy and development of targeted drug delivery systems. -
Drug-Linker Conjugate for ADC
DBCO-PEG4-VC-PAB-MMAE is a conjugate designed for use in antibody-drug conjugate (ADC) synthesis, incorporating a drug-linker element. The DBCO component facilitates strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with azide-containing molecules. The included MMAE moiety, a potent inhibitor of tubulin polymerization derived from dolastatin 10, exhibits significant mitotic inhibition. This reagent is ideal for advancing research in targeted cancer therapies by enabling the precise delivery of cytotoxic agents to tumor cells. -
Drug-Linker Conjugates for ADC
DBCO-PEG4-GGFG-Dxd is a drug-linker conjugate targeting antibody-drug conjugates (ADCs) with potent antitumor activity derived from the DNA topoisomerase I inhibitor Dxd. This compound utilizes a cleavable linker, DBCO-PEG4-GGFG, which enhances selective delivery of the therapeutic agent. DBCO-PEG4-GGFG-Dxd serves as a click chemistry reagent, featuring a DBCO moiety that facilitates strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules, making it a valuable tool in bioconjugation applications. -
Drug-Linker Conjugate for ADC
MC-VA-PAB-Exatecan is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It combines a peptide linker, MC-VA-PAB, with Exatecan, a potent inhibitor of DNA topoisomerase I, to enhance therapeutic efficacy. Synthesis of MC-VA-PAB-Exatecan-based ADCs demonstrates significant antitumor activity, making it a valuable tool for cancer research and drug development. -
Drug-Linker Conjugates for ADC
DL-01 formic is a versatile drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). It facilitates the covalent attachment of cytotoxic agents to antibodies, enhancing selective targeting of cancer cells. This reagent plays a crucial role in the development and optimization of ADC formulations for targeted cancer therapies, providing a means to improve therapeutic efficacy while minimizing off-target effects. -
Drug-Linker Conjugates for ADC
PB038 is a drug-linker conjugate featuring a polyethylene glycol (PEG) unit and a cleavable linker connected to Exatecan. This compound is designed to facilitate the targeted delivery of cytotoxic agents in antibody-drug conjugates (ADCs), enhancing therapeutic efficacy while minimizing off-target effects. PB038 is suitable for research applications focused on cancer therapeutics and drug development involving ADC technology. -
Drug-Linker Conjugates for ADC
Mc-VC-PAB-SN38 is a cleavable drug-linker conjugate that combines a linker (Mc-VC-PAB) with the potent DNA topoisomerase I inhibitor SN38. This compound is designed for the synthesis of antibody-drug conjugates (ADCs), providing a targeted approach for delivering therapeutic agents to malignant cells. Its unique structure facilitates the release of SN38 within the cellular environment, enhancing therapeutic efficacy while minimizing systemic toxicity. -
Drug-Linker Conjugate for ADC
MC-betaglucuronide-MMAE-1 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound exhibits potent antitumor activity through the action of MMAE, a tubulin polymerization inhibitor. The incorporation of the cleavable ADC linker MC-betaglucuronide enables targeted delivery and release of MMAE in tumor cells, enhancing therapeutic efficacy in cancer research. -
Drug-Linker Conjugate For ADC
MC-VA-PABC-MMAE is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound integrates the linker peptide MC-VA-PABC with the potent tubulin polymerization inhibitor MMAE, facilitating targeted delivery of the cytotoxic agent. It plays a crucial role in enhancing the therapeutic efficacy of ADCs in cancer research by selectively delivering MMAE to tumor cells while minimizing systemic toxicity. -
Drug-Linker Conjugate for ADC
Gly-Mal-GGFG-Deruxtecan 2-hydroxypropanamide is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound combines the ADC linker Gly-Mal-GGFG with the cytotoxic agent Deruxtecan 2-hydroxypropanamide, facilitating targeted delivery of therapeutic agents to cancer cells. It is primarily utilized in research focused on improving the efficacy and specificity of cancer therapies. -
Drug-Linker Conjugates for ADC
AZ14170133 is a drug-linker conjugate specifically designed for antibody-drug conjugates (ADCs). This compound comprises a cytotoxic payload, a topoisomerase 1 inhibitor, linked for effective targeted delivery. AZ14170133 is utilized in the synthesis of ADCs such as AZD9592 and AZD8205, making it a valuable tool for cancer research focused on developing innovative therapeutic strategies. -
Drug-Linker Conjugates for ADC
Gly3-VC-PAB-MMAE is a cleavable drug-linker conjugate comprising the linker Gly3-VC-PAB and the potent tubulin inhibitor MMAE. This compound facilitates the synthesis of antibody-drug conjugates (ADCs) by enabling targeted delivery of MMAE to cancer cells. Its unique structure allows for the selective release of the cytotoxic agent in the tumor microenvironment, making it valuable in cancer research and therapeutic development. -
Drug-Linker Conjugate for ADC
Mal-VC-PAB-DM1 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features DM1, a potent microtubule-disrupting agent, linked by the Mal-VC-PAB linker, which enhances targeted delivery to tumor cells. Mal-VC-PAB-DM1 exhibits significant antitumor activity, making it a valuable tool for cancer research and therapeutic development. -
Drug-Linker Conjugates for ADC
DBCO-PEG4-Val-Cit-PAB-MMAF is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs) that combines a cleavable PEG linker with the potent tubulin polymerization inhibitor MMAF. The DBCO moiety facilitates efficient synthesis through click chemistry, specifically strain-promoted alkyne-azide cycloaddition (SPAAC), allowing for precise conjugation to azide-containing biomolecules. This reagent is essential for enhancing the therapeutic efficacy of ADCs by enabling targeted delivery of cytotoxic agents. -
Drug-linker Conjugate for ADC
NH2-PEG3-VC-PAB-MMAE is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). It features a cleavable linker, NH2-PEG3-VC-PAB, which is linked to the potent tubulin inhibitor Monomethyl auristatin E (MMAE). This reagent is essential for facilitating targeted delivery and localized cytotoxicity in cancer research and therapeutic applications. -
Drug-Linker Conjugates for ADC
Mal-PEG8-Val-Cit-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features a cleavable linker that facilitates selective release of the potent tubulin inhibitor MMAE upon internalization by target cells. It is ideal for research aimed at improving the therapeutic index of ADCs through targeted delivery and enhanced cytotoxicity against cancer cells. -
Drug-Linker Conjugate for ADC
DBCO-PEG4-MMAF is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, utilizing MMAF as a potent tubulin polymerization inhibitor. The conjugate features a cleavable linker, DBCO-PEG4, which facilitates the selective release of MMAF within target cells. DBCO-PEG4-MMAF serves as a click chemistry reagent, containing a DBCO group that efficiently engages in strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-modified molecules, making it a valuable tool for targeted therapeutics in cancer research. -
Drug-Linker Conjugate for ADC
Mal-(CH2)5-Val-Cit-PAB-Eribulin is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, targeting microtubules to exert potent antitumor effects. The compound features the anti-microtubule agent Eribulin, which is covalently linked via the Mal-(CH2)5-Val-Cit-PAB linker. This strategic design enhances the therapeutic efficacy of Eribulin while minimizing systemic toxicity, making it a valuable tool for cancer research and development. -
Drug-Linker Conjugate for ADC
MC-Gly-Gly-Phe-Gly-(R)-Cyclopropane-Exatecan is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound features Exatecan, a potent inhibitor of DNA Topoisomerase I with an IC50 of 2.2 μM, which interferes with DNA replication and induces apoptosis in cancer cells. Its application in ADCs allows for targeted delivery of cytotoxic agents to tumor cells, enhancing therapeutic efficacy while minimizing off-target effects. -
Drug-Linker Conjugates for ADC
DBCO-(PEG2-VC-PAB-MMAE)2 is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound features Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, linked to a cleavable DBCO-(PEG2-VC-PAB)2 linker. The DBCO group enables efficient strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules, facilitating targeted delivery of cytotoxic agents. Its application is crucial for research in cancer therapeutics, particularly in enhancing the efficacy and selectivity of ADCs. -
Drug-Linker Conjugates for ADC
Mal-PEG4-VC-PAB-DMEA-PNU-159682 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound combines the ADC linker Mal-PEG4-VC-PAB with the cytotoxic agent DMEA-PNU-159682, which derives from metabolites of nemorubicin (MMDX) processed by liver microsomes. It exhibits strong cytotoxicity, making it suitable for targeted cancer therapies in research focused on ADC development and optimization. -
Drug-Linker Conjugates for ADC
Gly-Gly-Phe-Gly-NH-O-CO-Exatecan hydrochloride is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. The linker comprises Gly-Gly-Phe-Gly-NH-O-CO, which is attached to Exatecan, a potent inhibitor of DNA topoisomerase I. This compound exhibits significant potential in cancer research, facilitating targeted delivery and enhanced therapeutic efficacy in anticancer treatments. -
Drug-Linker Conjugates for ADC
Doxorubicin-SMCC is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs), featuring a non-cleavable linker and the anthracycline antibiotic Doxorubicin. Doxorubicin targets DNA topoisomerase II, interrupting DNA replication and transcription processes, which leads to cell death in rapidly dividing cancer cells. This reagent is valuable for research applications focused on targeted cancer therapies and the development of innovative drug delivery systems. -
Drug-Linker Conjugate For ADC
TCO-PEG4-VC-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features a cleavable linker (TCO-PEG4-VC-PA) that facilitates the release of the potent tubulin inhibitor MMAE upon cellular internalization. TCO-PEG4-VC-PAB-MMAE incorporates a TCO group suitable for inverse electron demand Diels-Alder (iEDDA) reactions, enabling highly specific conjugation with tetrazine-containing molecules, thus enhancing therapeutic efficacy in targeted treatments. -
Drug-Linker Conjugates for ADC
MC-EVCit-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugates (ADCs). This compound features the MC-EVCit-PAB linker combined with the potent tubulin polymerization inhibitor MMAE, which contributes to its cytotoxic properties. MC-EVCit-PAB-MMAE is utilized in research applications focused on targeted cancer therapies, enhancing the efficacy of ADCs through selective delivery of the chemotherapeutic agent. -
Drug-Linker Conjugates for ADC
MC-SN38 is a drug-linker conjugate that combines the potent microtubule-disrupting agent SN38 with a non-cleavable MC linker, designed for the development of antibody-drug conjugates (ADCs). SN38, a bioactive metabolite of the Topoisomerase I inhibitor Irinotecan, exerts its biological activity by inhibiting DNA synthesis and inducing DNA single-strand breaks. This compound is essential for research into targeted cancer therapies that leverage the specificity of antibodies to deliver cytotoxic agents to tumor cells. -
Drug-Linker Conjugate for ADC
SGD-1910 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It utilizes the antitumor antibiotic pyrrolobenzodiazepine (PBD), known for its cytotoxic DNA crosslinking activity, linked through the cleavable peptide MC-Val-Ala. This compound demonstrates significant potential in targeted cancer therapies by allowing for the precise delivery of cytotoxic agents, enhancing therapeutic efficacy while minimizing off-target effects. -
Drug-Linker Conjugate for ADC
DBCO-(PEG)3-VC-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugates (ADCs). This compound features Monomethyl auristatin E (MMAE) linked to a DBCO-(PEG)3-VC-PAB structure, facilitating targeted drug delivery in cancer research. As a click chemistry reagent, it utilizes a DBCO group that enables strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules, making it valuable in bioconjugation applications. -
Drug-Linker Conjugate for ADC
DBCO-PEG3-VC-Exatecan is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound combines the DBCO-PEG3-VC linker with Exatecan, a potent inhibitor of DNA topoisomerase I. Its structure facilitates targeted delivery of the cytotoxic agent to cancer cells, enhancing therapeutic efficacy while minimizing off-target effects. Research applications include the development of ADCs for cancer treatment, providing a strategic tool for targeted therapy and molecular oncology studies. -
Drug-Linker Conjugate for ADC
SC-VC-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This molecule features the potent antitumor agent monomethyl auristatin E (MMAE), a tubulin inhibitor that disrupts microtubule dynamics, linked through a cleavable SC-VC-PAB linker. SC-VC-PAB-MMAE demonstrates effective cytotoxicity in targeted cancer therapies, making it a valuable tool for research in oncology and ADC development.
